{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:03Z","timestamp":1761101103969},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T00:00:00Z","timestamp":1364169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T00:00:00Z","timestamp":1364169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/bmt.2013.39","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T11:43:04Z","timestamp":1364211784000},"page":"1192-1197","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival"],"prefix":"10.1038","volume":"48","author":[{"given":"Z A","family":"McIver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Battiwalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Koklanaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N F","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"John Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,25]]},"reference":[{"key":"BFbmt201339_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/ehm.10.32","volume":"3","author":"AJ Barrett","year":"2010","unstructured":"Barrett AJ, Battiwalla M . Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010; 3: 429\u2013441.","journal-title":"Expert Rev Hematol"},{"key":"BFbmt201339_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/bmt.2008.255","volume":"42","author":"BE Shaw","year":"2008","unstructured":"Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE et al. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. Bone Marrow Transplant 2008; 42: 783\u2013789.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201339_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.bmt.1705852","volume":"40","author":"DA Pollyea","year":"2007","unstructured":"Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 1027\u20131032.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201339_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.bbmt.2007.06.007","volume":"13","author":"M Mielcarek","year":"2007","unstructured":"Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ . Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplantation 2007; 13: 1160\u20131168.","journal-title":"Biol Blood Marrow Transplantation"},{"key":"BFbmt201339_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbmt.2006.09.005","volume":"13","author":"ML Arellano","year":"2007","unstructured":"Arellano ML, Langston A, Winton E, Flowers CR, Waller EK . Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol blood marrow transplant 2007; 13: 116\u2013123.","journal-title":"Biol blood marrow transplant"},{"key":"BFbmt201339_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S0140-6736(85)92865-X","volume":"1","author":"AJ Barrett","year":"1985","unstructured":"Barrett AJ, Joshi R, Tew C . How should acute lymphoblastic leukaemia relapsing after bone-marrow transplantation be treated? Lancet 1985; 1: 1188\u20131191.","journal-title":"Lancet"},{"key":"BFbmt201339_CR7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/leu.2009.185","volume":"23","author":"N Hijiya","year":"2009","unstructured":"Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia 2009; 23: 2259\u20132264.","journal-title":"Leukemia"},{"key":"BFbmt201339_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","volume":"41","author":"AW Loren","year":"2008","unstructured":"Loren AW, Porter DL . Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483\u2013493.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201339_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/MOH.0b013e32834b6158","volume":"18","author":"B Oran","year":"2011","unstructured":"Oran B, de Lima M . Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 2011; 18: 388\u2013394.","journal-title":"Curr Opin Hematol"},{"key":"BFbmt201339_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbmt.2003.08.011","volume":"10","author":"R Nakamura","year":"2004","unstructured":"Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant 2004; 10: 49\u201357.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201339_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/sj.bmt.1703928","volume":"31","author":"SR Solomon","year":"2003","unstructured":"Solomon SR, Nakamura R, Read EJ, Leitman SF, Carter C, Childs R et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 783\u2013788.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201339_CR12","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","volume":"26","author":"A Spyridonidis","year":"2012","unstructured":"Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia 2012; 26: 1211\u20131217.","journal-title":"Leukemia"},{"key":"BFbmt201339_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1517\/14712598.2011.554811","volume":"11","author":"C Roddie","year":"2011","unstructured":"Roddie C, Peggs KS . Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011; 11: 473\u2013487.","journal-title":"Expert Opin Biol Ther"},{"key":"BFbmt201339_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000253025","volume":"122","author":"M Hartwig","year":"2009","unstructured":"Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F et al. Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol 2009; 122: 185\u2013192.","journal-title":"Acta Haematol"},{"key":"BFbmt201339_CR15","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","volume":"21","author":"B Oran","year":"2007","unstructured":"Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21: 2540\u20132544.","journal-title":"Leukemia"},{"key":"BFbmt201339_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bmt.2012.195","volume":"48","author":"LM Poon","year":"2013","unstructured":"Poon LM, Bassett R Jr, Rondon G, Hamdi A, Qazilbash M, Hosing C et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 2013; 48: 666\u2013670.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201339_CR17","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119: 3361\u20133369.","journal-title":"Blood"},{"issue":"6","key":"BFbmt201339_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/leu.2013.7","volume":"27","author":"T Schroeder","year":"2013","unstructured":"Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia, (e-pub ahead of print 8 February 2013; doi:10.1038\/leu.2013.7).","journal-title":"Leukemia"},{"key":"BFbmt201339_CR19","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2010-10-265603","volume":"117","author":"V Gupta","year":"2011","unstructured":"Gupta V, Tallman MS, Weisdorf DJ . Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011; 117: 2307\u20132318.","journal-title":"Blood"},{"key":"BFbmt201339_CR20","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1182\/blood-2009-10-248997","volume":"115","author":"EH Warren","year":"2010","unstructured":"Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115: 3869\u20133878.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201339","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T17:23:02Z","timestamp":1648056182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,25]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFbmt201339"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.39","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,25]]},"assertion":[{"value":"13 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}